At the same time we see TIGIT targeted drugs failing, we are seeing the success of drugs against another white whale of cancer drug targets: KRAS.

It's the most frequently mutated cancer activating gene out there, but has been declared "undruggable" for the 15-20 years I've been close enough to drug developers to have heard about it.

Yet we're seeing clinical successes in recent trials with Revolution Medicine's daraxonrasib, and now there's blood in the water, with tons of new approaches going after it.

The progress in biotech in the past few decades has been unbelievable, and lots of things that were considered impossible a few decades ago are now happening left and right. Whenever I hear that somebody thinks that technological progress has stopped, I just think that they've stopped looking in the right places for the huge advances that are going on.

Agree. It's incredible that for pancreatic cancer (which is one of the single-most lethal and difficult-to-treat cancers there is) we're moving from a choice between a couple of decade-old and brutal chemotherapy cocktails, to discussions about sequencing and even the possibility of chemotherapy-free treatment, in a single generation of new agents.